key: cord-0894670-l4hhehqa
authors: Pitts, Jared; Li, Jiani; Perry, Jason K.; Du Pont, Venice; Riola, Nicholas; Rodriguez, Lauren; Lu, Xianghan; Kurhade, Chaitanya; Xie, Xuping; Camus, Gregory; Manhas, Savrina; Martin, Ross; Shi, Pei-Yong; Cihlar, Tomas; Porter, Danielle P.; Mo, Hongmei; Maiorova, Evguenia; Bilello, John P.
title: Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants
date: 2022-02-10
journal: bioRxiv
DOI: 10.1101/2022.02.09.479840
sha: 1e2c23fc06aaf11cd51ef663df81d9a23477127b
doc_id: 894670
cord_uid: l4hhehqa

Genetic variation of SARS-CoV-2 has resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of which Omicron is currently the predominant variant circulating worldwide. SARS-CoV-2 variants of concern or interest (VOC/VOI) have evidence of increased viral transmission, disease severity, or decreased effectiveness of vaccines and neutralizing antibodies. Remdesivir (RDV, VEKLURY®) is a nucleoside analog prodrug and the first FDA-approved antiviral treatment of COVID-19. Here we present a comprehensive antiviral activity assessment of RDV and its parent nucleoside, GS-441524, against 10 current and former SARS-CoV-2 VOC/VOI clinical isolates by nucleoprotein ELISA and plaque reduction assay. Delta and Omicron variants remained susceptible to RDV and GS-441524, with EC50 values 0.31 to 0.62-fold of those observed against the ancestral WA1 isolate. All other tested variants exhibited EC50 values ranging from 0.15 to 2.3-fold of the observed EC50 values against WA1. Analysis of nearly 6 million publicly available variant isolate sequences confirmed that Nsp12, the RNA-dependent RNA polymerase (RdRp) target of RDV and GS-441524, is highly conserved across variants with only 2 prevalent changes (P323L and G671S). Using recombinant viruses, both RDV and GS-441524 retained potency against all viruses containing frequent variant substitutions or their combination. Taken together, these results highlight the conserved nature of SARS-CoV-2 Nsp12 and provide evidence of sustained SARS-CoV-2 antiviral activity of RDV and GS-441524 across the tested variants. The observed pan-variant activity of RDV supports its continued use for the treatment of COVID-19 regardless of the SARS-CoV-2 variant.

In vitro RDV antiviral activity was assessed against clinical isolates of an extensive panel of past 93 and present SARS-CoV-2 VOC/VOIs (Supplemental Table 1 ). Antiviral activity was initially 94 assessed utilizing a plaque reduction assay (PRA) from culture supernatants harvested at 48 95 hours post-infection (hpi) from A549-ACE2-TMPRSS2 cultures infected with variants at an 96 MOI of 0.1. The average RDV EC50 value for the WA1 reference strain by PRA was 98 ± 48 97 nM, while variant EC50 values ranged from 15 to 154 nM, representing 0.15-to 1.6-fold changes 98 relative to WA1 (Table 1 and Fig. 1A ). These results indicate that RDV retains potent antiviral 99 activity against all variants evaluated by PRA, including the Delta variant, which was ~3-fold 100 more susceptible to RDV than the WA1 isolate.

To assess the antiviral effect directly in infected cultures, antiviral testing based on the 102 nucleoprotein (N) enzyme-linked immunoassay (ELISA) was developed and conducted in 103 addition to PRA. The EC50 of RDV against the WA1 reference strain by ELISA was 110 ± 42 104 nM (Table 1 and average RDV EC50 of 97 ± 15 nM. Thus, delaying the readout to 72 hpi had no effect on the 111 observed potency of RDV. The Omicron variant was significantly more susceptible to RDV with 112 an average EC50 value of 44 ± 16 nM (p≤0.0001), a 0.45-fold change compared to WA1. 113 The potency of GS-441524, the parent nucleoside of RDV, was also unchanged against all 114 variants and the WA1 reference isolate, as measured by ELISA at 48 hpi. The EC50 of 441524 at this timepoint against WA1 was 5600 ± 4100 nM and ranged from 2100 to 8790 nM 116 (0.53-to 1.43-fold change from WA1) against the collection of SARS-CoV-2 variants (Table 1, 117 Fig. 1C ). In agreement with the findings for RDV, GS-441524 was also found to be significantly 118 (p ≤0.0001) more potent against Omicron than WA1 at 72 hpi, with EC50 values of 3330 ± 1400 119 compared to 6240 ± 1300 nM for WA1. 121 To assess the genetic variation of Nsp12 in the 11 current or previously classified VOC/VOIs 122 (Omicron, Delta, Alpha, Beta, Gamma, Epsilon, Zeta, Iota, Kappa, Lambda, and Mu), a total of 123 5,842,948 SARS-CoV-2 variant sequences from the GISAID (Global Initiative on Sharing Avian 124 Influenza Data) database were evaluated. The highest proportion of analyzed sequences were 125 Delta variants (4,059,836; 69.5%), followed by Alpha variants (1,158,351; 19 .8%) and Omicron 126 variants (392,056; 6.7%); the other 8 variants made up the remaining 4.0% (Supplemental Table   127 2). We further assessed the genetic variation in spike in comparison to Nsp12 across the variants. which was observed in 97.8% of Delta isolates. No other substitutions were found with a 137 frequency of ≥50% in any of the variants. 138 Given the recent emergence and high prevalence of the Omicron variant, amino acid 139 substitutions in Nsp12 of Omicron variant were further investigated with a more sensitive 140 frequency cutoff of 0.5%. Among the 6 substitutions (Table 2) , P323L and F694Y were the most 141 frequently observed, in 99.5% and 2.0% of Omicron sequences, respectively, while all 4 142 remaining substitutions had frequencies of ≤1%. In the initial Omicron wave (December 13, 143 2021), F694Y was highly prevalent (41.1% of worldwide isolates and 94.1% of the UK isolates) 144 in sequences submitted to the GISAID database; however, as the Omicron variant continued to 145 spread, the G694Y substitution rapidly declined in frequency with only 2.00% of deposited 146 sequences harboring the substitution as of January 18, 2022 (Supplemental Fig. 2) . Interestingly, 147 F694Y is not unique to the Omicron variant as it was also found in 4.9% of Delta variant 148 sequences (Supplemental Table 2 ).

Most notably, Nsp12 substitutions previously identified to reduce in vitro susceptibility to RDV 150 (19, 35) , F480L, V557L, and E802D, were rarely found in our evaluation. Of the 5,842,948 151 variant sequences evaluated, F480L, V557L, and E802D were only observed in 16 (0.0002%), 152 24 (0.0004%), and 102 (0.002%) sequences, respectively. Further, only 49 (0.0008%) variant 153 sequences had any alteration at the residue involved in RDV induced delayed chain termination, 154 S861 (14). 156 RDV acts by incorporating its triphosphate metabolite (RDV-TP) into the viral RNA and 157 subsequently causing clashes with the Nsp12 protein at multiple location, compromising further 158 synthesis (14, 15). Analogs of RDV that produce the same RDV-TP active metabolite, such as 159 structure of the pre-incorporated state of RDV-TP in the RdRp active site is still unavailable. We 161 built a model, described previously (14, 15, 36) , based on an existing structure of the polymerase 162 complex (Nsp12/(Nsp8)2/Nsp7/(Nsp13)2) with primer and template RNA (PDB: 6XEZ) (37).

Using this model, we assessed the potential impact of each Nsp12 amino acid substitution 164 identified in the analyzed variants on the affinity of RDV-TP for the RdRp active site.

As seen in Fig. 2 , the two most common amino acid substitutions, P323L, seen in all variants, 166 and G671S, observed in Delta, are 28.6 Å and 24.9 Å, respectively, from the pre-incorporated 167 RDV-TP (measured from the amino acid Cα to RDV-TP's C1′). Of all the low-frequency 168 substitutions identified, only F694Y, found in 2-5% of Omicron and Delta isolates, is in close 169 proximity to the RdRp active site. Measured to be 12.2 Å from the RDV-TP, the residue is not in 170 direct contact with the inhibitor but is close enough to have an indirect conformational effect.

However, an evaluation of its impact on RDV-TP binding affinity using a molecular mechanics 172 generalized Born surface area (MM-GBSA) approach resulted in no meaningful difference, 173 likely because of the relatively conservative change from phenylalanine to tyrosine (38). The Omicron clinical isolate evaluated did not contain the Nsp12 F694Y substitution found at 181 high frequency in early UK Omicron isolates (Supplemental Fig. 2 ). Due to the initial prevalence in Omicron variants and proximity to the RdRp active site, we sought to assess RDV and GS-183 441524 activity against recombinant Omicron (rOmicron) viruses with and without the Nsp12 184 F694Y substitution. By ELISA, the RDV EC50 values were 46 ± 6 nM and 34 ± 3 nM (Table 3   185 and Fig. 3 (Table 4) . Collectively, these data confirm that antiviral potencies of RDV and GS-441524 208 remain unchanged against viruses harboring the prevalent Nsp12 substitutions currently 209 identified in isolates of SARS-CoV-2 variants. have an observed prevalence >15% among sequenced variant isolates (Supplemental Table 2 ). In All viruses were propagated 1-2 times in Vero-TMPRSS2 cells as follows. 1×10 7 Vero-292 TMPRSS2 cells were seeded into a T225 flask in Vero-TMPRSS2 maintenance media and 293 incubated overnight at 37⁰C + 5% CO2. The following day, the media was aspirated and replaced 294 with 25 mL of DMEM supplemented with 2% FBS (infection medium) and infected with 10 µL 295 of P0 stocks. The flasks were returned to 37⁰C + 5% CO2 until only 10-20% of viable cells 296 remained (typically 36-72 hpi). The supernatant was harvested into a 50 mL Falcon tube and 297 centrifuged at 2000 × g for 5 minutes to pellet cellular debris. The clarified supernatant was then 298 transferred to a clean falcon tube and aliquoted as a working P1 stock into 100-250 µL aliquots 299 and frozen at -80°C. The titer of the P1 stock was determined by plaque formation assay (PFA).

If a second passage was required, the procedure above was repeated using the P1 stock to 301 inoculate.

Plaque formation assay (PFA) 303 3×10 5 Vero-TMPRSS2 cells/well were seeded into 12-well plates in 1 mL of maintenance media 304 and incubated overnight at 37⁰C and 5% CO2. The following day, cell confluency was confirmed 305 to be >95% by visualization under a light microscope. Samples for analysis were serially diluted 306 10-fold in infection medium (DMEM + 2% FBS) up to a final dilution of 10 -5 or 10 -6 . Spent 307 supernatant was aspirated and replaced with 100 μL of serially diluted inoculum/well, and 308 culture plates were returned to the incubator for 1 h with gentle rocking every 15 min. Following 309 incubation, 2 mL of pre-warmed overlay medium (DMEM with 2% FBS, 1X 310 penicillin/streptomycin, and 1.5% carboxymethylcellulose) was added to each well. Cells were 311 then incubated without agitation for 3 days, at which point 2 mL of crystal violet fix/stain 312 solution was added to each well. Cells were incubated at room temperature overnight. The following day, media was aspirated and 100 µL of DMEM containing 2% FBS was added to 336 each well. Three-fold serial dilutions of RDV or GS-441524 (in triplicate) were added to each 337 well using a HP D300e digital dispenser with a final volume of 200 µL/well. Immediately after 338 compound addition, cells were infected with 1.5×10 3 PFU of the relevant SARS-CoV-2 variant 339 diluted in 100 µL of DMEM supplemented with 2% FBS, resulting in a MOI = 0.05. Plates were 340 centrifuged for 1 min at 500 × g and then incubated at 37⁰C with 5% CO2 for 2 days (or 3 days 341 for Omicron strains and 72 hpi WA1 reference), after which media was aspirated, and cells fixed 342 with 100% methanol for 10 minutes at room temperature (RT). The methanol was removed, and 359 The tabulated amino acid substitutions from WA1 reference (MN985325) for a total of 360 5,842,948 SARS-Cov-2 genome sequences were obtained from GISAID EpiCov database as of 361 January 18, 2021 (https://www.gisaid.org/) (47). Sequences with length <29,000 nucleotides in 362 length or that contained >5% of ambiguous bases across genome were excluded from analyses.

The sequences were further categorized into 11 VOC/VOIs according to the PANGO lineage 378 To produce recombinant SARS-CoV-2 virus, we utilized a SARS-CoV-2 reverse genetics system 379 previously described (24, 49) that was slightly modified by fusing plasmids F1-F3 single plasmid 

Recombinant Omicron SARS-CoV-2 was constructed by engineering the complete mutations isolate USA-WA1/2020 (50). All mutations were introduced into the infectious cDNA clone of 402 USA-WA1/2020 using PCR-based mutagenesis as previously described (51) . An additional recombinant Omicron SARS-CoV-2 was generated bearing the F694Y substitution in NSP12 by 404 the methods detailed above. rOmicron viruses were analyzed using the N-protein ELISA 405 following the protocol used for clinical isolates. CoV-2%20B.1.1.529-variant-concern-Omicron-for-the-EU-EEA-Nov2021.pdf. Table 3 . 708 Table 4 . 

Rapid selection of P323L in the SARS-CoV-2 polymerase (NSP12) in humans and non-human 613 primate models and confers a large plaque phenotype

Oral prodrug of remdesivir parent GS-441524 is efficacious 617 against SARS-CoV-2 in ferrets

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 622 pathogenesis in mice

Very low levels of remdesivir 624 resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 625 pandemic: A GISAID exploratory analysis

Omicron escapes the majority of 629 existing SARS-CoV-2 neutralizing antibodies

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited 633 human sera

Efficient multiplication of human metapneumovirus in Vero cells expressing 636 the transmembrane serine protease TMPRSS2

Exogenous ACE2 638 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus 639 replication

Data, disease and diplomacy: GISAID's innovative 641 contribution to global health

Aanensen 644 DM, Holmes EC, Pybus OG, Rambaut A. 2021. Assignment of epidemiological lineages in an 645 emerging pandemic using the pangolin tool

Engineering SARS-CoV-2 using a reverse genetic system

An Infectious cDNA Clone of SARS-CoV-2

Delta spike P681R mutation enhances SARS-CoV-2 653 fitness over Alpha variant

B.1.617.2 Source: UTMB Epsilon GNL-354 B.1.429 Source: UTMB Zeta hCoV

BEI (NR-55439) EPI_ISL_1364506